Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00577148 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
NCT00577148 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 89 participants.
The verdict
NCT00577148, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.
Interventions
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00577148
The ClinicalTrials.gov registry entry for NCT00577148 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimonabant is the first listed.
NCT00577148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00577148 about?
NCT00577148 is a clinical study titled "An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes". The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.
What is the current status of trial NCT00577148?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2008-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00577148?
The interventions under investigation include: Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00577148?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.